Abstract
The value of misonidazole in advanced head and neck cancer was examined in 3 ways and the preliminary results are reported in a randomized study with large fractions of irradiation, when misonidazole appeared to confer no advantage; whereas in previously (partially) treated patients misonidazole was possibly useful. The combination of hyperbaric oxygen and misonidazole did not appear to be toxic.